Drug–drug interactions involving antipsychotics and antihypertensives

References

• Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16:163–180.
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016;15:166–174.
   PubMed Web of Science ®Google Scholar
• De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8:114–126.
   Web of Science ®Google Scholar
• Vancampfort D, Firth J, Correll CU, et al. The impact of pharmacological and non‐pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta‐review of meta‐analyses of randomized controlled trials. World Psychiatry. 2019;18:53–66.
   PubMed Web of Science ®Google Scholar
• Rødevand L, Steen NE, Elvsåshagen T, et al. Cardiovascular risk remains high in schizophrenia with modest improvements in bipolar disorder during past decade. Acta Psychiatr Scand. 2019;139:348–360.
   PubMed Web of Science ®Google Scholar
• Jackson CA, Kerssens J, Fleetwood K, et al. Incidence of ischaemic heart disease and stroke among people with psychiatric disorders: retrospective cohort study. Br J Psychiatry. 2020;217:442–449.
   PubMedGoogle Scholar
• Salvi V, Aguglia A, Barone-Adesi F, et al. Cardiovascular risk in patients with severe mental illness in Italy. Eur Psychiatry. 2020;63:e96.
   PubMedGoogle Scholar
• Firth J, Siddiqi N, Koyanagi A, et al. The lancet psychiatry commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019;6:675–712.
   PubMed Web of Science ®Google Scholar
• Stubbs B, Vancampfort D, Hallgren M, et al. EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and position statement from the European Psychiatric Association (EPA), supported by the international organization of physical therapists in mental. Eur Psychiatry. 2018;54:124–144.
   PubMed Web of Science ®Google Scholar
• Pillinger T, Beck K, Gobjila C, et al. Impaired glucose homeostasis in first-episode schizophrenia. JAMA Psychiatry. 2017;74:261.
   PubMed Web of Science ®Google Scholar
• Pillinger T, Beck K, Stubbs B, et al. Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. Br J Psychiatry. 2017;211:339–349.
   PubMed Web of Science ®Google Scholar
• Alosaimi FD, Abalhassan M, Alhaddad B, et al. Prevalence of metabolic syndrome and its components among patients with various psychiatric diagnoses and treatments: a cross-sectional study. Gen Hosp Psychiatry. 2017;45:62–69.
   PubMed Web of Science ®Google Scholar
• Bresee LC, Majumdar SR, Patten SB, et al. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res. 2010;117:75–82.
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339–347.
   PubMed Web of Science ®Google Scholar
• Smith DJ, Martin D, McLean G, et al. Multimorbidity in bipolar disorder and undertreatment of cardiovascular disease: a cross sectional study. BMC Med. 2013;11:263.
   PubMedGoogle Scholar
• Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86:15–22.
   PubMed Web of Science ®Google Scholar
• Woodhead C, Ashworth M, Broadbent M, et al. Cardiovascular disease treatment among patients with severe mental illness: a data linkage study between primary and secondary care. Br J Gen Pract. 2016;66:e374–e381.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104.
   PubMed Web of Science ®Google Scholar
• Mensah GA, Bakris G. Treatment and control of high blood pressure in adults. Cardiol Clin. 2010;28:609–622.
   PubMedGoogle Scholar
• Lydon A, Vallely J, Tummon A, et al. Routine screening and rates of metabolic syndrome in patients treated with clozapine and long-acting injectable antipsychotic medications: a cross-sectional study. Ir J Psychol Med. 2021;38:40–48.
   PubMed Web of Science ®Google Scholar
• Scigliano G, Ronchetti G. Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. CNS Drugs. 2013;27:249–257.
   PubMed Web of Science ®Google Scholar
• Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17:97–107.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074–D1082.
   PubMed Web of Science ®Google Scholar
• Benet L. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115–121.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129–2200.
   PubMed Web of Science ®Google Scholar
• Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension. J Hypertens. 2015;33:1321–1341.
   PubMed Web of Science ®Google Scholar
• Toutain PL, Lefebvre HP. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors. J Vet Pharmacol Ther. 2004;27:515–525.
   PubMed Web of Science ®Google Scholar
• Li L, Li L, Shang D, et al. A systematic review and combined meta‐analysis of concentration of oral amisulpride. Br J Clin Pharmacol. 2020;86:668–678.
   PubMedGoogle Scholar
• Abraham G, Grunberg B, Gratz S. Possible Interaction of Clozapine and Lisinopril. Am J Psychiatry. 2001;158:969.
   PubMed Web of Science ®Google Scholar
• Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25:S12–S21.
   PubMed Web of Science ®Google Scholar
• Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–777.
   PubMed Web of Science ®Google Scholar
• White WB. Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril. Arch Intern Med. 1986;146:1833–1834.
   PubMedGoogle Scholar
• Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother. 2007;7:829–839.
   PubMedGoogle Scholar
• Silver H, Kogan H, Zlotogorski D. Postural hypotension in chronically medicated schizophrenics. J Clin Psychiatry. 1990;51:459–462.
   PubMedGoogle Scholar
• Aronowitz JS, Chakos MH, Safferman AZ, et al. Syncope associated with the combination of clozapine and enalapril. J Clin Psychopharmacol. 1994;14:429.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Sharma SG. Adverse Effects of Atypical Antipsychotics. CNS Drugs. 2007;21:911–936.
   PubMed Web of Science ®Google Scholar
• Thapa PB, Gideon P, Fought RL, et al. Psychotropic drugs and risk of recurrent falls in ambulatory nursing home residents. Am J Epidemiol. 1995;142:202–211.
   PubMed Web of Science ®Google Scholar
• Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411–1420.
   PubMed Web of Science ®Google Scholar
• Horowitz N, Molnar M, Levy Y, et al. Ramipril-induced agranulocytosis confirmed by a lymphocyte cytotoxicity test. Am J Med Sci. 2005;329:52–53.
   PubMedGoogle Scholar
• Hashmi HRT, Jabbour R, Schreiber Z, et al. Benazepril-induced agranulocytosis: a case report and review of the literature. Am J Case Rep. 2016;17:425–428.
   PubMedGoogle Scholar
• Hamidou M, Glemarec J, Elia-Foeillet S, et al. Agranulocytosis caused by perindopril. Ann Med Internet (Paris). 1996;147:523–524.
   PubMedGoogle Scholar
• Mijovic A, MacCabe JH. Clozapine-induced agranulocytosis. Ann Hematol. 2020;99:2477–2482.
   PubMedGoogle Scholar
• Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81:617–622.
   PubMed Web of Science ®Google Scholar
• Mishra B, Sahoo S, Sarkar S, et al. Clozapine-induced angioneurotic edema. Gen Hosp Psychiatry. 2007;29:78–80.
   PubMed Web of Science ®Google Scholar
• Cooney C, Nagy A. Drug points: angio-oedema associated with risperidone. BMJ. 1995;311:1204.
   PubMed Web of Science ®Google Scholar
• Soumya RN, Grover S, Dutt A, et al. Angioneurotic edema with risperidone: a case report and review of literature. Gen Hosp Psychiatry. 2010;32:646.e1–646.e3.
   Google Scholar
• Samra GS, Kant S, Chow R. Risperidone induced angioedema with concurrent EPS symptoms: a case report and review of literature. J Community Hosp Intern Med Perspect. 2018;8:80–83.
   PubMed Web of Science ®Google Scholar
• Muzyk AJ, Cvelich RG, Kincaid BR, et al. Angioedema occurring in patient prescribed iloperidone and haloperidol: a cross-sensitivity reaction to antipsychotics from different chemical classes. J Neuropsychiatry Clin Neurosci. 2012;24:E40–E41.
   PubMed Web of Science ®Google Scholar
• Srifuengfung M, Sukakul T, Liangcheep C, et al. Paliperidone palmitate-induced facial angioedema: a case report. World J Clin Cases. 2020;8:4876–4882.
   PubMedGoogle Scholar
• Williams GD. Cross-reaction of angioedema with clozapine, olanzapine, and quetiapine: a case report. Ment Heal Clin. 2019;9:315–317.
   PubMedGoogle Scholar
• Tatar ZB, Oflaz S, Baran B. A case of late-onset angioedema associated with clozapine and redevelopment of angioedema with olanzapine. J Clin Psychopharmacol. 2014;34:523–525.
   PubMedGoogle Scholar
• Kuoppala J, Enlund H, Pulkkinen J, et al. ACE inhibitors and the risk of acute pancreatitis-a population-based case-control study. Pharmacoepidemiol Drug Saf. 2017;26:853–857.
   PubMedGoogle Scholar
• Silva MA, Key S, Han E, et al. Acute pancreatitis associated with antipsychotic medication. J Clin Psychopharmacol. 2016;36:169–172.
   PubMedGoogle Scholar
• Dabaghi S. ACE inhibitors and pancreatitis. Ann Intern Med. 1991;115:330.
   PubMedGoogle Scholar
• Pemminati S, Swati B, Shreyasi C, et al. Co-administration of haloperidol and drugs affecting the angiotensin pathway: effect on the extrapyramidal system. Toxicol Mech Methods. 2012;22:139–143.
   PubMed Web of Science ®Google Scholar
• Izzedine H. Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature. Clin Pharmacol Ther. 2002;71:503–507.
   PubMed Web of Science ®Google Scholar
• Ramasamy I. Severe hyponatraemia during therapy with ramipril. Case Reports. 2009;2009:bcr0620091932–bcr0620091932.
   Google Scholar
• Falhammar H, Lindh JD, Calissendorff J, et al. Antipsychotics and severe hyponatremia: a Swedish population–based case–control study. Eur J Intern Med. 2019;60:71–77.
   PubMedGoogle Scholar
• Ali SN, Bazzano LA. Hyponatremia in association with second-generation antipsychotics: a systematic review of case reports. Ochsner J. 2018;18:230–235.
   PubMedGoogle Scholar
• Arivazhahan A, Bairy LK, Nayak V, et al. A study to assess the therapeutic effect of enalapril on olanzapine induced metabolic syndrome in Wistar rats. J Clin Diagn Res. 2017;11:FF01–FF06.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab BA, Metwally ME, El-khawanki MM, et al. Protective effect of captopril against clozapine-induced myocarditis in rats: role of oxidative stress, proinflammatory cytokines and DNA damage. Chem Biol Interact. 2014;216:43–52.
   PubMed Web of Science ®Google Scholar
• Liu X, Chen C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther. 2008;325:349–356.
   PubMed Web of Science ®Google Scholar
• Michel MC, Foster C, Brunner HR, et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013;65:809–848. Perez DM, editor.
   PubMed Web of Science ®Google Scholar
• Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol. 2001;41:823–832.
   PubMed Web of Science ®Google Scholar
• Ravyn D, Ravyn V, Lowney R, et al. CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. Schizophr Res. 2013;149:1–14.
   PubMed Web of Science ®Google Scholar
• Urichuk L, Prior T, Dursun S, et al. Metabolism of atypical antipsychotics: involvement of cytochrome P450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008;9:410–418.
   PubMed Web of Science ®Google Scholar
• Castaldelli-Maia JM, Hofmann C, Chagas ACP, et al. Major cardiac–psychiatric drug–drug interactions: a systematic review of the consistency of drug databases. Cardiovasc Drugs Ther. 2021;35:441–454.
   PubMedGoogle Scholar
• Siwek M, Woroń J, Gorostowicz A, et al. Adverse effects of interactions between antipsychotics and medications used in the treatment of cardiovascular disorders. Pharmacol Rep. 2020;72:350–359.
   PubMed Web of Science ®Google Scholar
• Preskorn S. Drug-drug interactions (DDIs) in psychiatric practice, part 7. J Psychiatr Pract. 2019;25:461–465.
   PubMedGoogle Scholar
• Wijesinghe R. A review of pharmacokinetic and pharmacodynamic interactions with antipsychotics. Ment Heal Clin. 2016;6:21–27.
   PubMedGoogle Scholar
• Silva Gracia M, Brandl R, Haen E. Lack of pharmacokinetic interaction between antipsychotics (quetiapine, clozapine and olanzapine) and the beta-blockers metoprolol, propranolol, bisoprolol and nebivolol except between carvedilol and the antipsychotics quetiapine and clozapine. J Anal Bioanal Tech. 2017;8. DOI:https://doi.org/10.4172/2155-9872.1000387
   Google Scholar
• Paulzen M, Haen E, Gründer G, et al. Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients – thinking of clinically relevant CYP2D6 interactions. J Psychopharmacol. 2016;30:803–809.
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Wells BG, Carson WH. Interactions between antipsychotic and antihypertensive drugs. Ann Pharmacother. 1995;29:603–609.
   PubMed Web of Science ®Google Scholar
• Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs. 2011;25:659–671.
   PubMed Web of Science ®Google Scholar
• Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17:341–356.
   PubMed Web of Science ®Google Scholar
• Nielsen J, Correll CU, Manu P, et al. Termination of clozapine treatment due to medical reasons. J Clin Psychiatry. 2013;74:603–613.
   PubMed Web of Science ®Google Scholar
• Davis BR, Oberman A, Blaufox MD, et al. Effect of antihypertensive therapy on weight loss. The trial of antihypertensive interventions and management research group. Hypertension. 1992;19:393–399.
   PubMed Web of Science ®Google Scholar
• Sharma AM, Pischon T, Hardt S, et al. Hypothesis: β-adrenergic receptor blockers and weight gain. Hypertension. 2001;37:250–254.
   PubMed Web of Science ®Google Scholar
• Leslie WS, Hankey CR, Lean MEJ. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. Qjm. 2007;100:395–404.
   PubMed Web of Science ®Google Scholar
• Manu P, Dima L, Shulman M, et al. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand. 2015;132:97–108.
   PubMed Web of Science ®Google Scholar
• Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64–77.
   PubMed Web of Science ®Google Scholar
• Rojo LE, Gaspar PA, Silva H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res. 2015;101:74–85.
   PubMed Web of Science ®Google Scholar
• Fonseca VA. Effects of β-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010;26:615–629.
   PubMed Web of Science ®Google Scholar
• Melkersson K, Dahl M-L. Adverse metabolic effects associated with atypical antipsychotics. Drugs. 2004;64:701–723.
   PubMed Web of Science ®Google Scholar
• Takeuchi Y, Kajiyama K, Ishiguro C, et al. Atypical antipsychotics and the risk of hyperlipidemia: a sequence symmetry analysis. Drug Saf. 2015;38:641–650.
   PubMedGoogle Scholar
• Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006;24:591–596.
   PubMed Web of Science ®Google Scholar
• La Torre A, Conca A, Duffy D, et al. Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry. 2013;46:201–208.
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939–951.
   PubMed Web of Science ®Google Scholar
• Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol. 2011;26:130–140.
   PubMedGoogle Scholar
• Fogari R. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens. 2001;14:27–31.
   PubMed Web of Science ®Google Scholar
• Erdmann E. Safety and tolerability of beta-blockers: prejudices & reality. Indian Heart J. 2010;62:132–135.
   PubMedGoogle Scholar
• La Torre A, Giupponi G, Duffy D, et al. Sexual dysfunction related to drugs: a critical review. part IV: cardiovascular drugs. Pharmacopsychiatry. 2014;48:1–6.
   PubMedGoogle Scholar
• Ferrario CM, Levy P. Sexual dysfunction in patients with hypertension: implications for therapy. J Clin Hypertens. 2002;4:424–432.
   PubMedGoogle Scholar
• Brixius K, Middeke M, Lichtenthal A, et al. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol. 2007;34:327–331.
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Weizman A. Treatment of antipsychotic-induced akathisia: role of serotonin 5-HT2a receptor antagonists. Drugs. 2020;80:871–882.
   PubMedGoogle Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Gardner D, Addington D, et al. The assessment and treatment of antipsychotic-induced akathisia. Can J Psychiatry. 2018;63:719–729.
   PubMed Web of Science ®Google Scholar
• Sica DA. Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. J Clin Hypertens. 2005;7:21–26.
   PubMedGoogle Scholar
• Wessler JD, Grip LT, Mendell J, et al. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013;61:2495–2502.
   PubMed Web of Science ®Google Scholar
• Blair HA. Lumateperone: first approval. Drugs. 2020;80:417–423.
   PubMed Web of Science ®Google Scholar
• Boulton DW, DeVane CL, Liston HL, et al. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002;71:163–169.
   PubMed Web of Science ®Google Scholar
• Nakagami T, Yasuifurukori N, Saito M, et al. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther. 2005;78:43–51.
   PubMed Web of Science ®Google Scholar
• Chiu -Y-Y, Ereshefsky L, Preskorn SH, et al. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabol Drug Interact. 2014;29. DOI:https://doi.org/10.1515/dmdi-2014-0005.
   Google Scholar
• Lorković H, Jäger U. Chlorpromazine and diltiazem effects in muscle: blockage of acetylcholine-evoked contractures, membrane currents and tracer calcium uptake. Pharmacology. 1996;53:11–18.
   PubMedGoogle Scholar
• Thorgeirsson G, Rudolph SA. Diltiazem-like effect of thioridazine on the dihydropyridine binding site of the calcium channel of rat myocardial membranes. Biochem Biophys Res Commun. 1984;121:657–663.
   PubMedGoogle Scholar
• Nakamura M, Seki M, Sato Y, et al. Quetiapine-induced bradycardia and hypotension in the elderly-A case report. Innov Clin Neurosci. 2016;13:34–36.
   PubMedGoogle Scholar
• Snarr BS, Phan SV, Garner A, et al. Symptomatic bradycardia with oral aripiprazole and oral ziprasidone. Ann Pharmacother. 2010;44:760–763.
   PubMed Web of Science ®Google Scholar
• Huang L-C, Huang L-Y, Tseng S-Y, et al. Amisulpride and symptomatic bradycardia: a case report. Gen Hosp Psychiatry. 2015;37:497.e1–497.e2.
   Google Scholar
• Umar MU, Abdullahi AT. Self-limiting atypical antipsychotics-induced edema: clinical cases and systematic review. Indian J Psychol Med. 2016;38:182–188.
   PubMedGoogle Scholar
• Erbas O, Yilmaz M. Metoprolol and diltiazem ameliorate ziprasidone-induced prolonged corrected QT interval in rats. Toxicol Ind Health. 2015;31:1152–1157.
   PubMedGoogle Scholar
• Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005;20:243–251.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs. 2002;62:1649–1671.
   PubMed Web of Science ®Google Scholar
• Bowman JD, Kim H, Bustamante JJ. Drug-Induced Gynecomastia. Pharmacother J Hum Pharmacol Drug Ther. 2012;32:1123–1140.
   Google Scholar
• Elliott WJ, Ram CVS. Calcium Channel Blockers. J Clin Hypertens. 2011;13:687–689.
   PubMed Web of Science ®Google Scholar
• Krevsky B, Maurer AH, Niewiarowski T, et al. Effect of verapamil on human intestinal transit. Dig Dis Sci. 1992;37:919–924.
   PubMed Web of Science ®Google Scholar
• Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013;27:879–911.
   PubMed Web of Science ®Google Scholar
• Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother. 2014;15:527–547.
   PubMed Web of Science ®Google Scholar
• Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother. 2014;15:605–621.
   PubMed Web of Science ®Google Scholar
• Vormfelde S, Engelhardt S, Zirk A, et al. Polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin Pharmacol Ther. 2004;76:557–566.
   PubMed Web of Science ®Google Scholar
• Hamrick I, Norton D, Birstler J, et al. Association between dehydration and falls. Mayo Clin Proc Innov Qual Outcomes. 2020;4:259–265.
   PubMedGoogle Scholar
• de Vries M, Seppala LJ, Daams JG, et al. Fall-risk-increasing drugs: a systematic review and meta-analysis: I. cardiovascular drugs. J Am Med Dir Assoc. 2018;19:371.e1–371.e9.
   Google Scholar
• Seppala LJ, Wermelink AMAT, de Vries M, et al. Fall-risk-increasing drugs: a systematic review and meta-analysis: II. psychotropics. J Am Med Dir Assoc. 2018;19:371.e11–371.e17.
   PubMed Web of Science ®Google Scholar
• Corponi F, Fabbri C, Bitter I, et al. Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019;29:971–985.
   PubMed Web of Science ®Google Scholar
• Madhusoodanan S, Bogunovic OJ, Moise D, et al. Hyponatraemia associated with psychotropic medications. Adverse Drug React Toxicol Rev. 2002;21:17–29.
   PubMedGoogle Scholar
• Mannesse CK, van Puijenbroek EP, Jansen PAF, et al. Hyponatraemia as an adverse drug reaction of antipsychotic drugs. Drug Saf. 2010;33:569–578.
   PubMedGoogle Scholar
• Proudman RGW, Pupo AS, Baker JG. The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D‐adrenoceptors. Pharmacol Res Perspect. 2020;8. DOI:https://doi.org/10.1002/prp2.602
   Google Scholar
• Claessens AJ, Risler LJ, Eyal S, et al. CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010;38:1393–1396.
   PubMed Web of Science ®Google Scholar
• Fruncillo RJ, Gibbons WJ, Vlasses PH, et al. Severe hypotension associated with concurrent clonidine and antipsychotic medication. Am J Psychiatry. 1985;142:274a–274 .
   PubMedGoogle Scholar
• Laurent S. Antihypertensive drugs. Pharmacol Res. 2017;124:116–125.
   PubMed Web of Science ®Google Scholar
• Srilatha B, Adaikan P, Arulkumaran S, et al. Sexual dysfunction related to antihypertensive agents: results from the animal model. Int J Impot Res. 1999;11:107–113.
   PubMed Web of Science ®Google Scholar
• Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and ARBs: managing potassium and renal function. Cleve Clin J Med. 2019;86:601–607.
   PubMedGoogle Scholar
• Coca A, Agabiti-Rosei E, Cifkova R, et al. The polypill in cardiovascular prevention. J Hypertens. 2017;35:1546–1553.
   PubMed Web of Science ®Google Scholar
• Saiz-Rodríguez M, Almenara S, Navares-Gómez M, et al. Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines. 2020;8:94.
   PubMed Web of Science ®Google Scholar
• Forster J, Duis J, Butler MG. Pharmacogenetic testing of cytochrome P450 drug metabolizing enzymes in a case series of patients with Prader-Willi syndrome. Genes (Basel). 2021;12:152.
   PubMedGoogle Scholar
• Kaar SJ, Natesan S, McCutcheon R, et al. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. 2020;172:107704.
   PubMed Web of Science ®Google Scholar
• Azizi M, Rossignol P, Hulot J-S. Emerging drug classes and their potential use in hypertension. Hypertension. 2019;74:1075–1083.
   PubMed Web of Science ®Google Scholar
• Wilcox CS. Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors. Hypertension. 2020;75:894–901.
   PubMed Web of Science ®Google Scholar